Combined antiretroviral therapy with nevirapine of HIV-infected adults


Cite item

Full Text

About the authors

A V Kravchenko

References

  1. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents, <http://www.hiatis.org> (accessed 4 February 2002).
  2. Nelson M. The role of NNRTls in antiretroviral combination therapy: an introduction. Int. J. STD and AIDS 2001; 12 (suppi. 4): 1-2.
  3. Van Leeuwen R. The Atlantic Study: A randomized, open-label trial comparing two protease inhibitor (Pl)-sparing antiretroviral strategies versus a standard Pi-containing regimen, 2 year follow-up data. In: XIV International AIDS conference. Barcelona; 2002. abstr. MoPeB3089.
  4. Podzamczer D. Final 12-month results from the COMBINE study: A randomized, open, multicenter trial comparing Combivir plus nelfinavir or nevirapine in naive Patients. 1st IAS conference on HIV pathogenesis and treatment. July 8-11, 2001. Buenos Aires. Buenos Aires; 2001. In: oral abstr. 7.
  5. Pollard R. and the 1090 Team. Factors predictive of durable HIV suppression in a randomized double blind trial with nevirapine (NVP), zidovudine (ZDV) and lamivudine (3TC) in treatment-naive (ARV-n) patients with advanced AIDS. In: 7"' Conference on retroviruses and opportunistic infections. San Francisco; 2000. abstr. 517.
  6. Mackie N., Sabin C., Weston R. et al. Durability and tolerability of nevirapine-containing regimens in a cohort of antiretroviral-naive HIV-positive patients. In: XIV International AIDS conference. Barcelona; 2002. abstr. TuPeB4443.
  7. Кравченко А. В., Саламов Г. Г., Богословская Е. В. и др. Трехкомпонентная комбинированная антиретровирусная терапия с применением ингибиторов обратной транскриптазы ВИЧ. Эпидемиол. и инфекц. бол. 2001; 4: 32- 35.
  8. Arribas J. Comparison of NNRTls in antiretroviral-na'ive patients. Int. J. STD and AIDS 2001; 12 (suppl. 4): 3-9.
  9. van Leth F., Hassink E., Phanuphak P. et al. Results of the 2NN study: A randomized comparative trial of first-line antiretroviral therapy with regimens containing either nevirapine alone, efavirenz alone or both drugs combined, together with stavudine and lamivudine. In: 10th Conference on retroviruses and opportunistic infections. February 10-14, 2003, Boston, Massachusetts. Boston; 2003. abstr. 176.
  10. Maggiolo F. Comparison of NNRTls in antiretroviral-expirienced patients. Int. J. STD and AIDS 2001; 12 (suppl. 4): 10-17.
  11. Negredo E., Cruz L., Paredes R. et al. Virological, immunological and clinical impact of switching from protease inhibitors to nevirapine or to efavirenz in patients with human immunodeficiency virus infection and long-lasting viral suppression. Clin. Infect. Dis. 2002; 34: 504-510.
  12. Hicks C., Brun S., King M. et al. Kaletra (Lopinavir/Ritonavir) therapy in single protease inhibitor experienced patients 144 week follow up. In: 8th ECAATH, 2001. Athens; 2001. abstr. P220.
  13. Khana N., Klimkait Т., Schiffer V. et al. Salvage therapy with abacavir plus a non-nucleoside reverse transcriptase inhibitor and a protease inhibitor or heavily pre-treated HIV-1 infected patients. Swiss HIV cohort study. AIDS 2000; 14: 791-799.
  14. Gymez A., Ncez M., Soriano V. et al. Toxicity of antiretroviral therapy (ART). 9 years experience. In: 7th ECAATH. Lisbon;1999. abstr. 577

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2004 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

 © 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies